Relentless Pursuit

“Pancreatic cancer will be cured. Advancements are happening every day. Many other cancers have been cured. This one will be too.”
— Daniel D. Von Hoff, M.D., F.A.C.P

With the establishment of The Daniel D. Von Hoff, M.D. Chair in Cancer Research, TGen proudly recognizes Dr. Von Hoff's remarkable contributions and significant advancements spanning nearly five decades. His groundbreaking discoveries and the development of novel anticancer agents, both within the laboratory and clinical settings, have solidified his unparalleled achievements.

Dr. Von Hoff's unwavering dedication is evident through his direct involvement in over 400 clinical trials, as well as his extensive publication record comprising over 741 papers, 143 book chapters, and more than 1186 abstracts. His transformative work has paved the way for significant milestones, including the approval of gemcitabine as the first treatment for pancreatic cancer and the FDA approval of three out of four drugs for advanced pancreatic cancer patients.

This esteemed chair serves as the ultimate recognition for preeminent scientists and clinicians, honoring their extraordinary accomplishments in their respective fields. It perpetuates the enduring legacy of Dr. Von Hoff, ensuring his profound impact will be felt for generations to come.

Contribute Now

THE RELENTLESS PURSUIT

In 2023, an estimated 64,050 Americans will receive a pancreatic cancer diagnosis, highlighting the formidable and persistent nature of this disease. Known for its challenges in early detection and treatment, pancreatic cancer holds the unfortunate distinction of having the highest mortality rate among major cancers. Currently, it is the 3rd leading cause of cancer-related death in the United States after lung and colon and is expected to become the 2nd by 2030.

Throughout his storied career, Dr. Von Hoff's exceptional research and clinical practice have consistently pushed the boundaries of biomedical knowledge and education. Today, his groundbreaking contributions and ongoing work continue to play a pivotal role in advancing the early detection and treatment of numerous cancers, including this relentless disease.

TESTIMONIALS

“In addition to his brilliance, he is a loyal and supportive colleague. This has contributed to his special relationships with both senior and junior colleagues over the years. People have always wanted to “go to the mat” for Dan because he always makes time for people when they need him.”

Margaret “Marge” Foti, Ph.D., M.D. Chief Executive Officer American Association for Cancer Research

YOUR IMPACT

The Relentless Pursuit initiative creates The Daniel D. Von Hoff, M.D. Endowed Chair in Cancer Research, a testament to Dr. Von Hoff's exceptional career at TGen and within the larger medical and research community. The endowed chair position, with a focus on pancreatic cancer, ensures this vital work remains at the forefront of TGen’s commitment to early detection, smarter treatments and better outcomes for patients.

Contribute Now